{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:00:51Z","timestamp":1786546851849,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Lantern Pharma Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04937-2","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T01:57:24Z","timestamp":1786499844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial"],"prefix":"10.1007","volume":"96","author":[{"given":"Jianli","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daruka","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Ewesuedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"4937_CR1","doi-asserted-by":"publisher","first-page":"115476","DOI":"10.1016\/j.addr.2024.115476","volume":"216","author":"H Liu","year":"2025","unstructured":"Liu H, Ibrahim EIK, Centanni M et al (2025) Integrated modeling of biomarkers, survival and safety in clinical oncology drug development. Adv Drug Deliv Rev 216:115476. https:\/\/doi.org\/10.1016\/j.addr.2024.115476","journal-title":"Adv Drug Deliv Rev"},{"key":"4937_CR2","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2020","unstructured":"Friberg LE, Henningsson A, Maas H et al (2020) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713\u20134721. https:\/\/doi.org\/10.1200\/JCO.2002.02.140","journal-title":"J Clin Oncol"},{"key":"4937_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/1535-7163.MCT-22-0818","volume":"22","author":"D Restifo","year":"2023","unstructured":"Restifo D, McDermott JR, Cvetkovic D et al (2023) Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies. Mol Cancer Ther 22:1182\u20131190. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0818","journal-title":"Mol Cancer Ther"},{"key":"4937_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2767-9764.CRC-23-0554","volume":"4","author":"A Kulkarni","year":"2024","unstructured":"Kulkarni A, Zhou J, Biyani N et al (2024) LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency. Cancer Res Commun 4:1199\u20131210. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0554","journal-title":"Cancer Res Commun"},{"key":"4937_CR5","doi-asserted-by":"crossref","unstructured":"Mahadevan D, Parekh J, Beck JT, McKean WB Jr, Schreck K, Olszanski AJ, Shields MD, Phan V, Hamm JT, Bank BB, Zhou J, Chamberlain M, Bhatia K, Ewesuedo R (2026) A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors. Accepted for publication in investigational new drugs","DOI":"10.1007\/s10637-026-01626-y"},{"key":"4937_CR6","doi-asserted-by":"publisher","unstructured":"Liu S, Yuan Y (2015) Bayesian optimal interval designs for phase I clinical trials. J R Stat Soc: Ser C (Appl Stat). 64:507\u2013523. https:\/\/doi.org\/10.1111\/rssc.12089","DOI":"10.1111\/rssc.12089"},{"key":"4937_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10928-015-9432-2","volume":"42","author":"W Denney","year":"2015","unstructured":"Denney W, Duvvuri S, Buckeridge C (2015) Simple, Automatic Noncompartmental Analysis: The PKNCA R Package. J Pharmacokinet Pharmacodyn 42:11\u2013107. https:\/\/doi.org\/10.1007\/s10928-015-9432-2. S65. ISSN 1573\u20138744","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4937_CR8","unstructured":"US (2017) Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. November 27 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"4937_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2307\/1412159","volume":"15","author":"C Spearman","year":"1904","unstructured":"Spearman C (1904) The proof and measurement of association between two things. Am J Psychol 15:72\u2013101","journal-title":"Am J Psychol"},{"key":"4937_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2307\/2982890","volume":"155","author":"GJG Upton","year":"1992","unstructured":"Upton GJG (1992) Fisher\u2019s Exact Test. J R Stat Soc Ser Stat Soc 155:395\u2013402","journal-title":"J R Stat Soc Ser Stat Soc"},{"key":"4937_CR11","unstructured":"Heinze G, Ploner M, Jiricka L, Steiner G (2025) logistf: Firth\u2019s Bias-Reduced Logistic Regression. R package version 1.26.1. https:\/\/github.com\/georgheinze\/logistf"},{"issue":"12","key":"4937_CR12","doi-asserted-by":"publisher","first-page":"e0314452","DOI":"10.1371\/journal.pone.0314452","volume":"19","author":"V Danesi","year":"2024","unstructured":"Danesi V, Andal\u00f2 A, Cavallucci M et al (2024) Body weight and body surface area of adult patients with selected cancers: An Italian multicenter study. PLoS ONE 19(12):e0314452 Published 2024 Dec 17. https:\/\/doi.org\/10.1371\/journal.pone.0314452","journal-title":"PLoS ONE"},{"key":"4937_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/1078155219861423","volume":"26","author":"A Razzaghdoust","year":"2020","unstructured":"Razzaghdoust A, Mofid B, Zangeneh M (2020) Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma. J Oncol Pharm Pract 26:587\u2013594. https:\/\/doi.org\/10.1177\/1078155219861423","journal-title":"J Oncol Pharm Pract"},{"key":"4937_CR14","unstructured":"Colvin M (2003) Alkylating Agents. In: Kufe DW, Pollock RE, Weichselbaum RR, editors. Holland-Frei Cancer Medicine, 6th edition. Hamilton, BC Decker. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK12772\/"},{"key":"4937_CR15","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-03-0349","volume":"10","author":"J Alexandre","year":"2004","unstructured":"Alexandre J, Raymond E, Kaci MO et al (2004) Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin Cancer Res 10:3377\u20133385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0349","journal-title":"Clin Cancer Res"},{"key":"4937_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.biocel.2014.05.017","volume":"53","author":"R S\u00e1nchez-Rodr\u00edguez","year":"2014","unstructured":"S\u00e1nchez-Rodr\u00edguez R, Torres-Mena JE, De-la-Luz-Cruz M et al (2014) Increased expression of prostaglandin reductase 1 in hepatocellular carcinomas from clinical cases and experimental tumors in rats. Int J Biochem Cell Biol 53:186\u2013194. https:\/\/doi.org\/10.1016\/j.biocel.2014.05.017","journal-title":"Int J Biochem Cell Biol"},{"key":"4937_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.18632\/oncotarget.28454","volume":"14","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sturtevant D, Love C et al (2023) LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin\u2019s lymphoma models and in cells deficient in DNA damage repair. Oncotarget 14:597\u2013611. https:\/\/doi.org\/10.18632\/oncotarget.28454","journal-title":"Oncotarget"},{"key":"4937_CR18","unstructured":"Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (2020) Temozolomide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548816\/"},{"key":"4937_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/1471-2407-6-234","volume":"6","author":"D Pouliquen","year":"2006","unstructured":"Pouliquen D, Olivier C, Debien E, Meflah K, Vallette FM, Menanteau J (2006) Changes in liver mitochondrial plasticity induced by brain tumor. BMC Cancer 6:234. https:\/\/doi.org\/10.1186\/1471-2407-6-234","journal-title":"BMC Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04937-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04937-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04937-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:03:39Z","timestamp":1786543419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04937-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4937"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04937-2","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.Z, M.C, K.B., and R.E. are salaried employees of Lantern Pharma Inc. and are entitled to hold stock options in the company. J.Z. and K.B. are named inventors on several intellectual properties by Lantern Pharma Inc.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical standards in the Declaration of Helsinki and applicable Good Clinical Practice guidelines. The study protocol was approved by the appropriate institutional and\/or national research ethics committee.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients or their legal representatives before enrollment.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"88"}}